PharmAust Expands Site Recruitment for Phase II Pet Dog Cancer Trial
PharmAust Ltd (ASX:PAA), a clinical-stage oncology company developing targeted cancer therapeutics for humans and animals, reports that it has expanded site recruitment for its anti-cancer trial in pet dogs with treatment naïve B cell lymphoma.
The company’s lead drug candidate is Monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a key driver of cancer.
MPL has been evaluated in Phase 1 clinical trials in both humans and dogs. It was well tolerated and produced a significant reduction in key prognostic biomarkers. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug in Phase 2 clinical trials. MPL is a repurposed drug that’s already approved for veterinary use by Elanco Animal Health.
With the additional participating sites and an associated advertising campaign, PharmAust now expects the pace of recruitment of canine patients to be increased.
In conjunction with the trial manager, U-Vet in Werribee, and through the University of Melbourne’s Department of Veterinary Clinical Sciences, PharmAust has now also contracted the University Veterinary Teaching Hospital at the University of Sydney (UVTHS) as well as the West Australian Veterinary Emergency and Specialists (WAVES) in Perth.
The UVTHS site will be run by Dr Peter Bennett and the WAVES site will be run by Dr Sue Bennett (no relation). Dr Peter Bennett is one of Australia’s leading cancer clinical trial specialists and both sites are highly acknowledged and recognised for their work in treating veterinary cancer.
With the addition of these two sites, PharmAust now has central referral sites within Victoria, New South Wales (two including the previously announced Animal Referral Hospital in Homebush, Sydney) and Western Australia.
The company anticipate this national network to facilitate and expedite the generation of meaningful and successful outcomes for this trial.
In further supporting this network and expediting recruitment, PharmAust has also engaged a pet journalist and has commenced an aggressive marketing awareness campaign to vets and pet owners.
PharmAust’s Chief Scientific Officer Dr Richard Mollard stated: “PharmAust is pleased and excited to have the support and involvement of Dr Peter Bennett and Dr Sue Bennett. Having the participation of such highly accredited veterinarians and hospitals is a tribute to the diligent preclinical and clinical work PharmAust has executed preparing monepantel for re-entry into the clinic for this pivotal trial. PharmAust is looking forward to reporting meaningful and successful outcomes to the market.”
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.